Annual International Congress on Hematologic Malignancies | Conferences

Future of Myelofibrosis Treatment is Moving Beyond Just JAK Inhibition

February 27, 2022

The future of myelofibrosis may include several JAK inhibitor treatment niches as well as combination regimens with JAK inhibition in both the upfront and second-line setting and more, according to John Mascarenhas, MD.

Subgroup Analysis Improves Understanding of Frontline DLBCL Options

February 25, 2022

Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma, and while many trials have failed to change the standard of care and improve outcomes, new opportunities for targeted treatment are growing, according to Brian T. Hill, MD, PhD.

Careful Data Review Recommended for Upfront Treatment Selection in iNHL

February 29, 2020

To enhance outcomes for patients with indolent non-Hodgkin lymphoma, an in-depth review of the available data is required. As a start, Sonali M. Smith, MD, University of Chicago Medicine, reviewed the clinical trial findings that are currently informing treatment selection in the frontline iNHL paradigm, at 24th Annual International Congress on Hematologic Malignancies.